9,610 reports of this reaction
1.4% of all ABATACEPT reports
#16 most reported adverse reaction
SWELLING is the #16 most commonly reported adverse reaction for ABATACEPT, manufactured by E.R. Squibb & Sons, L.L.C.. There are 9,610 FDA adverse event reports linking ABATACEPT to SWELLING. This represents approximately 1.4% of all 665,237 adverse event reports for this drug.
Patients taking ABATACEPT who experience swelling should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SWELLING is a less commonly reported adverse event for ABATACEPT, but still significant enough to appear in the safety profile.
In addition to swelling, the following adverse reactions have been reported for ABATACEPT:
The following drugs have also been linked to swelling in FDA adverse event reports:
SWELLING has been reported as an adverse event in 9,610 FDA reports for ABATACEPT. This does not prove causation, but indicates an association observed in post-market surveillance data.
SWELLING accounts for approximately 1.4% of all adverse event reports for ABATACEPT, making it a notable side effect.
If you experience swelling while taking ABATACEPT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.